메뉴 건너뛰기




Volumn 94, Issue 3, 2013, Pages 297-300

The PCAST report on pharmaceutical innovation: Implications for the FDA

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; MEDICAL RESEARCH; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; REVIEW; DRUG INDUSTRY; GOVERNMENT REGULATION; INVENTION; PUBLIC-PRIVATE PARTNERSHIP; UNITED STATES;

EID: 84883143935     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.88     Document Type: Review
Times cited : (12)

References (9)
  • 1
    • 84883168834 scopus 로고    scopus 로고
    • Executive office of the president, president's council of advisors on science and technology 25 September 2012
    • Executive Office of the President, President's Council of Advisors on Science and Technology. Propelling innovation in drug discovery, development and evaluation (25 September 2012).
    • Propelling Innovation in Drug Discovery, Development and Evaluation
  • 2
    • 79960100831 scopus 로고    scopus 로고
    • Reengineering translational science: The time is right
    • Collins, F.S. Reengineering translational science: the time is right. Sci. Transl. Med. 6, 90cm17 (2011).
    • (2011) Sci. Transl. Med , vol.6
    • Collins, F.S.1
  • 5
    • 84865433971 scopus 로고    scopus 로고
    • US Food and Drug Administration (5 March 2013) Accessed 4 April 2013
    • US Food and Drug Administration. Biomarker qualification program (5 March 2013). Accessed 4 April 2013.
    • Biomarker Qualification Program
  • 7
    • 84883186414 scopus 로고    scopus 로고
    • US Food and Drug Administration Safety and Innovation 126 Stat993 9 July 2012
    • US Food and Drug Administration Safety and Innovation Act. Pub. L. No. 112-44, 126 Stat. 993 (9 July 2012).
    • Act. Pub. L. NO. 112-44
  • 8
    • 84883180484 scopus 로고    scopus 로고
    • Creating an alternative approval pathway for certain drugs intended to address unmet medical need
    • US Food and Drug Administration 4 February 2013
    • US Food and Drug Administration. Creating an alternative approval pathway for certain drugs intended to address unmet medical need. Public hearing. (4 February 2013).
    • Public Hearing
  • 9
    • 78149349684 scopus 로고    scopus 로고
    • US Food and Drug Administration 20 May 2013 Accessed 4 April 2013
    • US Food and Drug Administration. FDA's Sentinel Initiative (20 May 2013). Accessed 4 April 2013.
    • FDA's Sentinel Initiative


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.